Pancreatic Cancer Trial, Recruiting NCT07045571 Sponsor: Yingbin Liu, MD, PhD, FACS Condition: Pancreatic Cancer
Back to Pancreatic Cancer

Pancreatic Cancer Trial, Recruiting

NCT07045571
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged between 18 and 80 years old
  • People who have been found to have a growth or mass in the pancreas through imaging scans, where a malignant (cancerous) tumour is strongly suspected, and who are planned to have surgery or a tissue sample (biopsy) taken for further testing
  • People who have at least one tumour that can be measured on a CT scan, where the largest tumour is at least 10mm across
  • People who are able to provide tumour tissue and blood samples for the study
  • People who are generally well and able to carry out normal daily activities with little or no limitation (confirm with trial site for exact fitness assessment)
  • People whose liver function, kidney function, and blood counts fall within acceptable ranges as assessed by the trial site (confirm with trial site for specific values)
  • People of childbearing age who are willing to use contraception during the trial; women of childbearing age must have a negative pregnancy test within 7 days before joining
  • People who are willing to participate and able to follow the study requirements; if someone cannot sign the consent form themselves, a legal representative may do so on their behalf with the person's knowledge

Who may not be able to join:

  • People who are unable to provide tumour tissue or blood samples
  • People who have previously received targeted therapy, immunotherapy, or anti-cancer chemotherapy or radiotherapy before this study
  • People who have a history of any other cancer besides pancreatic cancer
  • People who have serious heart conditions, such as severe heart failure, unstable chest pain, poorly controlled irregular heartbeat, or high blood pressure that is not well controlled
  • People with diabetes that is not well controlled
  • People who currently have an active infection
  • People with active autoimmune diseases (where the immune system attacks the body) that require long-term use of steroid medications
  • People who have previously had an organ or tissue transplant from another person
  • People with active mental health conditions that may affect their ability to give informed consent or follow the study plan
  • People who have other serious illnesses that the study doctors consider unsuitable for participation

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Yinbin Liu, PhD, RenJi Hospital

Phone: +86 13918803900

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Yingbin Liu, MD, PhD, FACS
Registry
ClinicalTrials.gov
Start date
30 October 2022
Est. completion
22 January 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Sensitivity and Specificity of ctDNA in Early Screening for Pancreatic Cancer; Sensitivity and Specificity of ctDNA Methylation Test for Detection of Postoperative Recurrence

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov